Gemcitabine in metastatic nasopharyngeal carcinoma of the ...
Recommend Documents
Jun 28, 2013 - Tel: +86-10-87787039; Fax: +86-10- ... on the ICD-10 topography code C11. ..... among the Chinese, probably because of Epstein-Barr virus.
2011;41(8):672-721. Epub 2011 Jun 2. 11. Jia WH, Luo XY, Feng BJ, Ruan HL, Bei JX, Liu WS, et al. Traditional Cantonese diet and nasopharyngeal carcinoma.
Nasopharyngeal carcinoma (NPC) is one of the most common cancers in Malaysia, a country in Southeast. Asia with a multiracial population.
Radiation Oncology, Benavides Cancer Institute, University of Santo. Tomas Hospital .... The AJCC/UICC 7th edition[4] was used to determine clinical stage.
Nasopharyngeal carcinoma (NPC) is one of the most common cancers in Malaysia, a country in Southeast Asia with a multiracial population.
Sep 19, 2010 - Sofia M Haryana1, Servi JC Stevens3, Astrid E Greijer2, Jaap M ...... Baarle D, Hovenkamp E, Dukers NH, Renwick N, Kersten MJ, Goudsmit J,.
Nasopharyngeal Carcinoma, Multiple Cranial ... almost all cranial nerves without either sensory or ... through right foramen ovale and foramen rotundum.
ABSTRACT Nasopharyngeal carcinoma is commonly advanced at diagnosis. ... diagnostic delay and factors affecting delay in nasopharyngeal carcinoma.
Gemcitabine in metastatic nasopharyngeal carcinoma of the ...
with metastatic nasopharyngeal carcinoma (NPC) to evaluate the tumour ... Conclusions: Gemcitabine has moderate activity in NPC with minimal toxicity, and is ...
Original article
Annals of Oncology 13: 150–156, 2002 DOI: 10.1093/annonc/mdf002
Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type K.-F. Foo1, E.-H. Tan1*, S.-S. Leong1, J. T. S. Wee2, T. Tan2, K.-W. Fong2, L. Koh3, B.-C. Tai4, L.-G. Lian2,4 & D. Machin3,4 1
Department of Medical Oncology, 2Department of Therapeutic Radiology, 3Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore; 4National Medical Research Council, Clinical Trials and Epidemiology Research Unit, Singapore Received 10 April 2001; revised 3 August 2001; accepted 20 August 2001
Background: We conducted two parallel phase II trials in chemonaïve and previously treated patients with metastatic nasopharyngeal carcinoma (NPC) to evaluate the tumour response, progression-free and overall survival, and toxicity of gemcitabine. Patients and methods: Gemcitabine 1250 mg/m2 was given on days 1 and 8 of a 21-day cycle. Patients with an Eastern Cooperative Oncology Group performance status 100 000/mm3), adequate renal function (serum creatinine level
